Compliance & Validation — Not documented by Atlas
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
Early-stage AI platform that automates Investigational New Drug preparation, generating pre-IND packets and CTD submodules.
Symbia, founded in 2024 and headquartered in San Francisco, California, is an early-stage (Y Combinator) company that automates the preparation of Investigational New Drug (IND) applications, importing source documents and generating pre-IND packets and Common Technical Document (CTD) submodules through an interactive review interface. As a pre-seed company, its scale and enterprise readiness should be assessed directly. Atlas found no vendor-held security certifications documented on its site; generated documents require regulatory-team review before submission.
50% — Partial coverage. Coverage score — how completely Atlas documents Symbia across 7 buyer-evaluation areas. Reflects available Atlas data, not solution quality.
Ask the vendor: Which compliance certifications (HIPAA, 21 CFR Part 11, SOC 2, GxP) do you hold?
cloud
Ask the vendor: What is your pricing model, and what drives total cost of ownership?
Ask the vendor: What is a realistic implementation timeline, and what onboarding support is included?
Biotech Startup, Mid-Size Biotech, Regulatory Affairs
Regulatory Submission Authoring
Pre-seed, Founded 2024
Not captured in Atlas data — confirm directly. Excluded from the score above.
Who owns model outputs? Is our proprietary data used to train models others can access, and where does our data reside?
Can you share validation studies or benchmarks, explain how the model reaches its conclusions, and describe how bias and drift are monitored?